ESH CLL 2022 – Pierre Feugier

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Pierre Feugier explains which patients with CLL should preferably be treated with targeted agents rather than with chemotherapy or chemoimmunotherapy, the advantages of second-generation BTK inhibitors as compared to first-generation BTK inhibitors and discusses third-generation BTK inhibitors as well as his personal highlights reported at ESH CLL 2022.

Here is the full ESH CLL 2022 report.

More posts